High efficacy of gefitinib in the treatment of EGFR mutation-positive advanced non-small cell lung adenocarcinoma: A case report

Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs), such as gefitinib and erlotinib, are known to play a significant role in EGFR mutation-positive non-small cell lung cancer. When an EGFR mutation is found, gefitinib and erlotinib have been shown to have significant roles in...

Descripción completa

Detalles Bibliográficos
Autores principales: WANG, ZHONGCHAO, CHU, JIANJUN
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2014
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4114712/
https://www.ncbi.nlm.nih.gov/pubmed/25120716
http://dx.doi.org/10.3892/ol.2014.2269

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4114712/
https://www.ncbi.nlm.nih.gov/pubmed/25120716
http://dx.doi.org/10.3892/ol.2014.2269

Ejemplares similares